Connected health platform operator Trellus Health on Monday announced the launch of its direct-to-consumer offering in the New York tri-state area, for people with Crohn’s disease and ulcerative colitis.
Listed company AIM said the service would provide its “resilience-based methodology” to support clinical treatment plans for adult patients through care coordination, behavioral skills training, expert training on diseases and remote monitoring of patients.
He said the program would include personalized care plans for the whole person, the HIPAA-compliant “TrellusElevate” digital platform, telehealth services and remote access to an expert licensed care team, including a registered nurse. educator, behavioral health counsellor, dietitian and resilience coach.
Initially, Trellus would offer enrollment to patients over the age of 17 in New York, New Jersey and Connecticut, with plans to expand to more than 20 states by the end of the year.
The council said that with more than 30 million residents, the tri-state area contains “one of the highest concentrations” of people living with IBD in the United States, about 250,000 patients.
Trellus said it is partnering with Connected Health Medicine to provide clinical telehealth services using licensed healthcare professionals.
Fees for accessing and participating in the company’s direct-to-consumer service would be paid directly by patients or reimbursed by health insurance using existing current procedural terminology (CPT) codes with some commercial insurance plans.
He said direct-to-consumer pricing was lower on average than value-based business-to-business contract fees, and a reduced introductory monthly membership rate was offered to boost early outreach and recruitment.
As it has already indicated in its December update, Trellus will focus in 2022 on recruiting patients directly from consumers and establishing additional demonstration programs and business-to-business contracts.
This, the board said, would allow Trellus to gather “real-world evidence” to validate and reinforce the quality of health and economic outcomes indicated in the research published by the co-founders, as well as to inform further product development.
“IBD is a debilitating and incurable disease that requires behavioral support to cope with the complexity and challenges of daily life,” said Executive Director Monique Fayad.
“Trellus Health partners with IBD patients and their gastrointestinal service providers, offering behavioral, nutritional, and clinical monitoring support and tools beyond traditional episodic medical care, with the goal of empowering patients, improve outcomes and reduce the need for unscheduled hospital and emergency room visits.
“Healthcare providers can view Trellus as a trusted extension of their gastroenterology practice that helps improve care plan adherence and outcomes through remote patient monitoring and access to comprehensive care.” indispensable. »
At 13:10 GMT, Trellus Health shares were up 3.36% at 30.49p.